Skip to main content
Harbin Pharmaceutical Group Co.,Ltd. logo

Harbin Pharmaceutical Group Co.,Ltd. — Investor Relations & Filings

Ticker · 600664 ISIN · CNE0000009T3 LEI · 300300G0L086UJ23MI26 Shanghai Stock Exchange Manufacturing
Open in API
Filings indexed 1,824 across all filing types
Latest filing 2024-08-22 Capital/Financing Update
Country CN China
Listing Shanghai Stock Exchange 600664

About Harbin Pharmaceutical Group Co.,Ltd.

https://www.hayao.com/

Harbin Pharmaceutical Group Co., Ltd. specializes in the research, development, manufacture, and distribution of a diverse range of pharmaceutical and healthcare products. The company's portfolio includes antibiotics, over-the-counter (OTC) medicines, health supplements, traditional Chinese medicines, and animal health products. It operates through several specialized subsidiaries and maintains a significant presence in the production of penicillins and cephalosporins. A key strategic focus involves the health and nutrition sector, bolstered by the acquisition of global nutrition brand GNC. The company leverages large-scale manufacturing capabilities and an extensive distribution network to serve both domestic and international markets. Its operations emphasize technological innovation and quality control across its integrated supply chain, from raw material production to finished dosage forms.

Recent filings

Filing Released Lang Actions
哈药集团股份有限公司关于哈药集团三精大庆玻璃工业园有限公司检验工序自动化升级项目建设的公告
Capital/Financing Update Classification · 95% confidence The document is an announcement regarding an investment project by 哈药集团股份有限公司 (Harbin Pharmaceutical Group Co., Ltd.) for an automation upgrade in a subsidiary's production process. It details the investment amount, project description, risk analysis, and impact on the company. The document is relatively short (2377 characters) and does not contain financial statements or detailed financial performance data. It is an announcement of a capital expenditure project, specifically an investment update related to the company's operations and capital use. There is no indication that this is a full financial report, audit report, or regulatory filing. The content fits best under Capital/Financing Update (CAP) as it informs investors about a capital investment project and its funding source.
2024-08-22 Chinese
哈药集团股份有限公司关于哈药中药研究院规划改造项目建设的公告
Capital/Financing Update Classification · 95% confidence The document is an announcement regarding an investment project for the planning and renovation of a traditional Chinese medicine research institute by the company 哈药集团股份有限公司. It details the investment amount, project overview, risk analysis, and impact on the company. The document is relatively short (2813 characters) and does not contain financial statements or detailed financial performance data. It is an announcement of a capital investment project rather than a financial report or earnings release. It does not fit categories like Annual Report, Interim Report, Earnings Release, or Management Reports. It is best classified as a Capital/Financing Update (CAP) because it provides an update on a capital investment project and funding source.
2024-08-22 Chinese
哈药集团股份有限公司十届四次监事会决议公告
Regulatory Filings Classification · 95% confidence The document is a supervisory board resolution announcement from Harbin Pharmaceutical Group Co., Ltd. It details the supervisory board's approval of the company's 2024 half-year report, asset impairment provisions, and asset write-offs. The document is short (912 characters) and primarily serves as an announcement of the supervisory board's review and approval of the half-year report rather than containing the full financial report itself. It does not include detailed financial statements or substantive financial data but rather the supervisory board's opinions and resolutions. Therefore, it is not an Interim/Quarterly Report (IR) but an announcement related to the report. Given the short length and nature of the content, this fits best under Regulatory Filings (RNS), which is the fallback category for such announcements that do not contain the full report or detailed financial data.
2024-08-22 Chinese
哈药集团股份有限公司关于哈药集团制药六厂南直路厂区供暖入网项目建设的公告
Capital/Financing Update Classification · 95% confidence The document is an announcement by 哈药集团股份有限公司 regarding the construction of a heating network project at one of its factory locations. It details the investment amount, project overview, risk analysis, and impact on the company. The document is relatively short (2618 characters) and focuses on informing investors about a specific capital investment project. It does not contain financial statements, audit information, or detailed financial results. It is not a report but an announcement about a capital expenditure project. Therefore, it fits best under the category of Capital/Financing Update (CAP).
2024-08-22 Chinese
哈药集团股份有限公司关于哈药集团制药六厂南直路厂区公用工程改造项目建设的公告
Capital/Financing Update Classification · 95% confidence The document is an announcement from 哈药集团股份有限公司 regarding an investment project for the renovation of public engineering facilities at one of its factory sites. It details the investment amount, project purpose, risk factors, and impact on the company. The document is relatively short (2508 characters) and does not contain financial statements or detailed financial performance data. It is an announcement about a capital expenditure project rather than a financial report or earnings release. It does not fit categories like Annual Report, Interim Report, Earnings Release, or Management Reports. It is best classified as a Capital/Financing Update (CAP) because it provides an update on a capital investment project and its financing source (self-funded).
2024-08-22 Chinese
哈药集团股份有限公司2024年半年度报告_摘要
Interim / Quarterly Report Classification · 95% confidence The document is titled as a '2024 半年度报告摘要' which translates to '2024 Semi-Annual Report Summary'. It contains detailed financial data for the half-year period, including total assets, net profit, earnings per share, and shareholder information. The document explicitly states it is a summary of the half-year report and advises investors to read the full semi-annual report on the official exchange website. The length is 2470 characters, which is relatively short, but it contains substantive financial data and analysis, not just an announcement or a link to a report. The document is unaudited and includes financial metrics comparing the current period to the previous year. This fits the definition of an Interim / Quarterly Report (IR), which is a comprehensive financial report for a period shorter than a full fiscal year containing actual financial statements and substantive financial data. Therefore, the correct classification is IR with high confidence. H1 2024
2024-08-22 Chinese

Browse filings by year

27 years

Report missing filing

Can't find a specific document? Let us know and we'll add it within 24 hours.

We will notify you once the filing is added.
Report sent
Thank you. We will check the data and update it shortly.